Gail Roboz

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA. Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital. Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Michal Bar-Natan, MD, is Associate Professor (Pending Appointment at Rank) of Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City.
Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.
Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute.
Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.

Dr. Alexandra Gomez-Arteaga is an Assistant Professor at Weill Cornell Medicine/NewYork-Presbyterian Hospital and directs the Allogeneic Bone Marrow Transplant Service and the Advanced Fellowship in Bone Marrow Transplantation. She earned her MD from Los Andes University, completed her residency at the University of Miami, her Hematology/Oncology fellowship at Weill Cornell, and her BMT advanced fellowship at Memorial Sloan Kettering Cancer Center. Dr. Gomez’s research focuses on improving outcomes in allogeneic stem cell transplantation for leukemia and myeloid malignancies, with an emphasis on young adults and alternative donors. Her work also addresses the critical need to decrease disparities in access to transplantation for minority populations, a cause she champions across her clinical practice, research, and advocacy. She currently serves as the Co-Chair for the Junior Faculty Initiative within the ASTCT ACCESS Initiative.

Dr. Elias Jabbour is Professor of Medicine and Chief of the Acute Lymphoblastic Leukemia (ALL) Section in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. A world-renowned physician-scientist, he has authored more than 1,000 peer-reviewed publications and is recognized internationally for pioneering advances in the treatment of acute and chronic leukemias.

Over his career, Dr. Jabbour has led pivotal clinical trials that resulted in the approval of multiple therapies for CML, MDS, and ALL, transforming standards of care and improving patient survival worldwide. His groundbreaking work includes defining resistance mechanisms to TKIs, establishing novel frontline regimens for CML, and developing innovative targeted and combination therapies for ALL, including strategies that have significantly advanced outcomes for patients with Philadelphia chromosome–positive ALL.

Through his leadership and vision, Dr. Jabbour continues to shape the field of hematologic oncology, driving forward the integration of precision medicine and next-generation therapeutics to improve outcomes for patients across the globe.

Dr. Marlise Luskin received her MD from the University of Pennsylvania Perelman School of Medicine in 2009. She completed residency and chief residency in Internal Medicine at Brigham and Women’s Hospital in 2012, followed by fellowship training in Hematology and Oncology at the University of Pennsylvania in 2015. In 2016, she joined the Division of Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts, where she cares for patients with leukemia. Dr. Luskin's clinical and research interests include acute lymphoblastic leukemia, acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, chronic myeloid leukemia, and the care of young adults with leukemia. Dr. Luskin is also Associate Program Director of the Dana-Farber/MGB Hematology/Oncology Fellowship, Director of the Foley Family Fellowship in Leukemia, and Education Director for the Division of Leukemia.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA. Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital. Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA. Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital. Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Pinkal Desai MD, MPH is an Associate Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the New York-Presbyterian Hospital. She is the Clinical Director of Molecular Aging Institute at the Einglander Institue of Prescision Medicine, WCM. Dr. Desai serves in the Leukemia Program and has a clinical practice devoted to leukemia, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). She is actively involved in clinical and translational research protocols and projects in the areas of leukemia, MDS and MPN. Her expertise is in the clinical care of patients with these diseases and she serves as principal investigator and co-investigator of numerous investigator initiated and industry-sponsored clinical trials.

Dr. Desai’s research interests are in hematological malignancies particularly in the fields of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and clonal hematopoiesis (CH). In addition she has a background in epidemiology and has a strong research interest in the epidemiology of hematological malignancies, particularly in studying preventative strategies in hematological malignancies with numerous publications in the field of cancer epidemiology.

Dr. Desai is published in Nature Medicine, Journal of Clinical Oncology, British Journal of Haematology, Blood Advances, Cancer, Cancer Medicine, Cancer Epidemiology Biomarkers Prevention and International Journal of Molecular Epidemiology and Genetics. She is a member of American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) and has served on the ASCO University Committee.

Dr. Madhu Ouseph is currently an assistant professor of pathology and laboratory medicine at Weill Cornell Medical College, New York. He completed his medical training at Mahatma Gandhi University and the University of Delhi in India and his research training at The Ohio State University, followed by Anatomic and Clinical Pathology residency training at Brown University, a Hematopathology fellowship at Brigham and Women's Hospital/Harvard University, and a Molecular Genetic Pathology fellowship at Stanford University. In his current position at Weill Cornell Medicine, his clinical activities are primarily centered in hematopathology and molecular pathology. He serves as Director for Molecular Hematopathology and Associate Director for the Division of Molecular Pathology. Dr. Ouseph's research interests are broad, focused on unraveling the molecular mechanisms underlying hematological disorders, identifying novel therapeutic and prognostic markers, and developing new clinical assays; this work has cumulatively led to close to 55 peer-reviewed publications. He is a member of the Education Committee at the Society for Hematopathology (SH), the Publications Committee at the Association for Molecular Pathology (AMP), and the Molecular Oncology Committee at the College of American Pathologists (CAP).

Eytan M. Stein, MD is the Chief of the Leukemia Service, Attending Physician, Clinical Investigator, and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. Dr. Stein led the clinical studies of the IDH2 inhibitor Enasidenib, the IDH1 Inhibitor Ivosidenib, and the menin inhibitor Revumenib in patients with relapsed and refractory AML that led to their FDA approvals. He leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the BEAT AML master clinical trial. His current research focuses on elucidating mechanisms of resistance to Menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery and Blood.

Eunice S. Wang, MD is Chief of the Leukemia Service and Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center. She directs the Roswell Park Hematological Procurement Shared Resource and is Physician Leader for the Roswell Park Chemotherapy/Infusion center. She also serves as an associate professor in the Department of Medicine, Jacobs School of Medicine, University of Buffalo, Buffalo, NY. Dr. Wang earned her medical degree from the Keck (University of Southern California) School of Medicine and completed internal medicine residency at Yale-New Haven Hospital followed by hematology-oncology fellowship training at Memorial Sloan Kettering Cancer Center, NY, NY.

Morton Coleman, MD is the Founding Chair, LL&M Congress. He has been an Attending Physician at the New York-Presbyterian Hospital/Weill Cornell Medical Center and a Clinical Professor of Medicine at Weill Cornell Medicine. He was the Director of the Center for Lymphoma and Myeloma, the chairman of the Medical Affiliates Board of the Lymphoma Research Foundation, President of the New York Cancer Society, the chairman of Clinical Research Alliance, among many prestigious appointments. He has served on numerous scientific boards. Dr Coleman has received numerous awards including those from the Cure for Lymphoma Foundation, the Lymphoma Research Foundation, The Waldenstrom's Foundation, Cornell University and Old Dominion University among others. He has authored hundreds of publications primarily in myeloma, lymphoma, and chronic lymphocytic leukemia. Among his many seminal observations were the development of the standard of care for Hodgkin disease for over 40 years, the first use of effective novel agents in myeloma, metronomic therapy for hematologic diseases, and the use of combination monoclonal antibody therapy, among others. He founded the Lymphoma, Leukemia, and Myeloma Conference a quarter of a century ago.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA. Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital. Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA. Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital. Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Morton Coleman, MD is the Founding Chair, LL&M Congress. He has been an Attending Physician at the New York-Presbyterian Hospital/Weill Cornell Medical Center and a Clinical Professor of Medicine at Weill Cornell Medicine. He was the Director of the Center for Lymphoma and Myeloma, the chairman of the Medical Affiliates Board of the Lymphoma Research Foundation, President of the New York Cancer Society, the chairman of Clinical Research Alliance, among many prestigious appointments. He has served on numerous scientific boards. Dr Coleman has received numerous awards including those from the Cure for Lymphoma Foundation, the Lymphoma Research Foundation, The Waldenstrom's Foundation, Cornell University and Old Dominion University among others. He has authored hundreds of publications primarily in myeloma, lymphoma, and chronic lymphocytic leukemia. Among his many seminal observations were the development of the standard of care for Hodgkin disease for over 40 years, the first use of effective novel agents in myeloma, metronomic therapy for hematologic diseases, and the use of combination monoclonal antibody therapy, among others. He founded the Lymphoma, Leukemia, and Myeloma Conference a quarter of a century ago.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA. Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital. Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Ghaith Abu-Zeinah, MD, is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine (WCM) and a member of the Richard T Silver Myeloproliferative Neoplasms (MPN) Center at WCM. He specializes in the care of patients with MPNs, including polycythemia vera, essential thrombocythemia, and myelofibrosis. His clinical and translational research focuses on disease modification, molecular response, clonal evolution, and the development of personalized treatment strategies through clinical trials and real-world data. Dr. Abu-Zeinah has authored several peer-reviewed publications, serves as an investigator on national and international clinical trials, serves on a national guidelines committee, and has received honors recognizing his contributions to the field of MPNs, including the American Society of Hematology (ASH) Scholar Award and the MPN Hero Award. He is committed to advancing innovative therapies while improving outcomes and quality of life for patients with MPNs through collaborative research, education, and compassionate patient care.

Dr. John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. Dr. Mascarenhas is the Director of Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. As a clinical investigator in malignant hematology with a focus in translational research involving MPNs, he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr. Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary acute leukemia.

Gail J. Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA. Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital. Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Dr. Beck is an Assistant Professor in the Center for Human Genetics and Genomics, and the Department of Medicine, Division of Rheumatology at New York University Grossman School of Medicine. Prior to his joining the faculty at NYU, Dr. Beck was a postdoctoral fellow in the lab of Dr. Dan Kastner at the National Institutes of Health, where he helped in identify the role of somatic mutations in autoinflammatory diseases. He completed his B.A. from Brown University, and M.D. and Ph.D. in Biochemistry in the Medical Scientist Training Program at NYU with Dr. Danny Reinberg. He completed his Internal Medicine training at Columbia University as part of the Clinician Scientist Pathway and his Clinical Genetics fellowship at the National Institutes of Health. Dr. Beck’s research interests focus on trying to identify genetic causes of diseases in patients with rheumatic diseases, and using laboratory investigation to help provide insights for clinical care. He runs a translational program studying autoinflammatory diseases, including VEXAS syndrome, both in the clinic and in the laboratory. His work has won awards from National Institutes of Health, the Arthritis Research Foundation, Burroughs Wellcome Fund Career Award for Medical Scientist and the Henry Kunkel Society to name a few.

Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine / Stanford Cancer Institute. His medical school, internal medicine, and hematology/oncology fellowship training were undertaken at Stanford, where he also earned a master’s degree in clinical epidemiology.

His research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). Dr. Gotlib has authored more than 250 research articles, chapters, and reviews that have been published in journals including Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. He is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and chaired the NCCN guideline development for SM. He led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. Dr. Gotlib was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year in 2019 for the development of KIT-targeting therapies in advanced SM.

Dr. Gotlib currently serves as President of the American Initiative in Mast Cell Diseases (AIM). He is actively involved with the American Society of Hematology where he has served as Editor-in-Chief of ASH’s The Hematologist, was Educational Co-Chair for the 2019 annual meeting and currently serves as Associate Editor for Blood. Dr. Gotlib enjoys landscape photography in his spare time.

Dr. Kaner is the Director of the Inpatient Leukemia Service at Weill Cornell Medicine. He is also Director of the HLH Consult service and the HLH clinical and translational research program. He specializes in the diagnosis and management of inpatients with acute leukemias (ALL,AML, APL, MPAL, AUL), and other bone marrow disorders including aplastic anemia, MDS, CML, MPN and HLH. In addition, Dr. Kaner is the Associate Director of the Hematology and Medical Oncology Fellowship Program.

Dr. Kaner is a clinical investigator and focuses his clinical and research practice on improving outcomes for patients with various types of acute leukemia and hemophagocytic lymphohistiocytosis.